Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001140361-25-000626
Chunk: 21

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B3
Chunk 21
---
 million, or approximately $(8.29) per share of Common Stock based upon 23,896,525 basic shares outstanding as of such date. Net tangible book value per share is equal to our total tangible assets, less our total liabilities, divided by the total number of basic shares outstanding. After giving effect to the assumed sale of our Common Stock in the aggregate amount of $100 million at an assumed offering price of $20.12 per share, the last reported sale price of our Common Stock on Nasdaq on December 12, 2024, and after deducting commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of September 30, 2024 would have been $(101.2) million, or $(3.51) per share of Common Stock. This represents an immediate increase in net tangible book value of $4.78 per share to our existing stockholders and an immediate dilution in net tangible book value of $23.63 per share to investors in this offering. The following table illustrates these calculations on a per-share basis. The as adjusted information is illustrative only and will depend on the actual price to the public, the actual number of shares sold and other terms of the offering determined at the time shares of our Common Stock are sold pursuant to this prospectus. The as adjusted information assumes that all of our Common Stock in the aggregate amount of $100 million is sold at the assumed offering price of $20.12 per share, the last reported sale price of our Common Stock on Nasdaq on December 12, 2024. The shares sold in this offering, if any, will be sold from time to time at various prices.

| Assumed public offering price per share                                           
 Net tangible book value per share as of September 30, 2024                        |     | $(8.29) |     | $20.12 |
|:----------------------------------------------------------------------------------|:----|--------:|:----|-------:|
| Increase in net tangible book value per share attributable to the offering        |     |    4.78 |     |        |
| As adjusted net tangible book value per share after giving effect to the offering |     |         |     |  -3.51 |
| Dilution per share to investors participating in this offering                    |     |         |     | $23.63 |

The number of shares of our Common Stock to be outstanding immediately after this offering is based on 23,896,525 shares of our Common Stock outstanding